autoimmun
retinopathi
air
rare
immunemedi
retinopathi
associ
circul
antiretin
antibodi
ara
promin
featur
air
includ
visual
field
deficit
photoreceptor
dysfunct
set
progress
unexplain
vision
loss
role
inflamm
poorli
understood
air
sinc
cytokin
play
central
role
initi
develop
inflamm
evalu
presenc
proinflammatori
cytokin
chemokin
air
patient
sera
demonstr
elev
air
patient
sera
moreov
presenc
concentr
molecul
appear
correl
air
patient
diseas
sever
cytokin
profil
describ
particip
varieti
autoimmun
inflammatori
diseas
studi
provid
support
activ
inflammatori
process
air
identifi
possibl
mechan
drive
autoimmun
diseas
autoimmun
retinopathi
air
inflammatorymedi
retinopathi
character
otherwis
unexplain
progress
vision
loss
abnorm
photoreceptor
function
presenc
serum
antiretin
antibodi
case
ophthalm
exam
includ
retin
exam
unremark
make
diagnosi
difficult
comlekoglu
et
al
autoimmun
retinopathi
classifi
paraneoplast
pair
cancer
associ
retinopathi
melanoma
associ
retinopathi
nonparaneoplast
air
npair
grang
et
al
purpos
studi
focu
latter
sinc
first
report
two
decad
ago
npair
remain
illdefin
disord
despit
unremark
exam
earli
diseas
cours
patient
abnorm
electroretinographi
visual
field
fox
et
al
typic
patient
chorioretin
lesion
may
lowgrad
intraocular
inflamm
diseas
progress
retin
atrophi
retin
vascular
attenu
optic
disc
pallor
may
ensu
along
vision
loss
interestingli
antiretin
antibodi
also
found
healthi
control
patient
degen
retin
disord
patient
system
autoimmun
diseas
ocular
diseas
heckenl
et
al
shimazaki
et
al
thu
unlik
paraneoplast
air
specif
role
antiretin
antibodi
npair
poorli
understood
clinic
respons
immunomodulatori
agent
also
variabl
cast
doubt
inflammatori
natur
diseas
nevertheless
antiretin
antibodi
visual
dysfunct
hallmark
npair
patient
typic
treat
immunomodulatori
agent
hope
slow
progress
diseas
forooghian
et
al
davoudi
et
al
adamu
gener
critic
compon
autoimmun
diseas
inflammatori
disord
dysregul
immun
respons
lead
inflamm
year
sever
key
cytokin
increasingli
identifi
mediat
inflamm
hunter
jone
newer
technolog
includ
multiplex
cytokin
platform
made
cytokin
test
access
clinic
sampl
multifunct
cytokin
display
broad
divers
rang
biolog
activ
includ
control
cell
growth
cell
surviv
hunter
jone
addit
shown
mediat
regul
immun
system
notabl
prolifer
activ
cytotox
cell
growth
differenti
memori
b
cell
plasma
cell
furthermor
especi
wellknown
abil
trigger
inflamm
inducung
acut
phase
respons
way
impact
acut
perhap
chronic
inflamm
although
often
consid
potent
inflammatori
cytokin
also
demonstr
antiinflammatori
properti
complex
signal
system
consist
two
distinct
signal
pathway
depend
cell
type
differ
pathway
initi
recent
antagonist
antibodi
develop
block
bind
receptor
amelior
inflamm
varieti
cell
produc
sever
stimuli
trigger
product
cytokin
ie
tlr
ligat
hunter
jone
year
data
gener
support
associ
autoimmun
diseas
hirano
exampl
pathway
implic
pathogenesi
rheumatoid
arthriti
ra
psoriasi
autoimmun
liver
diseas
crohn
diseas
tanaka
kishimoto
studi
reveal
number
serum
intraocular
cytokin
chemokin
vegf
report
elev
ocular
inflammatori
diseas
jawad
et
al
recent
identifi
contributor
inflammatori
process
ifntrigg
chemokin
member
chemokin
superfamili
small
protein
particip
immun
inflammatori
reaction
specif
induct
cell
nk
cell
migrat
ifn
molecul
upregul
ifn
signatur
gene
frequent
seen
major
factor
autoimmun
diseas
system
lupu
erythemat
sle
hook
et
al
niewold
addit
describ
play
role
pathogenesi
certain
autoimmun
diseas
includ
ra
giant
cell
arter
sle
simpson
et
al
loo
et
al
order
evalu
possibl
inflammatori
compon
air
screen
presenc
gmcsf
multiplex
immunoassay
report
demonstr
eia
upregul
air
patient
sera
moreov
show
attract
cell
specif
target
organ
also
elev
diseas
presenc
concentr
cytokin
signatur
appear
correl
air
patient
diseas
sever
data
support
concept
two
bioregulatori
molecul
may
contribut
patholog
process
observ
air
patient
air
patient
seen
uveiti
clinic
nation
eye
institut
includ
patient
provid
written
inform
consent
particip
research
studi
patient
seen
clinic
research
protocol
approv
institut
review
board
nation
institut
health
nih
adher
tenet
declar
helsinki
compli
health
insur
portabl
account
act
hipaa
patient
met
criteria
air
determin
consensu
sever
uveiti
expert
includ
neg
malign
workup
confirm
posit
antiretin
antibodi
air
defin
absenc
fundu
abnorm
abnorm
electroretinogram
erg
goldman
peripher
visual
field
gvf
presenc
circul
antiretin
antibodi
fox
et
al
cohort
includ
patient
differ
clinic
stage
diseas
earli
late
stage
sever
patient
least
one
antiretin
antibodi
detect
western
blot
posit
immunohistochem
stain
patient
test
posit
multipl
antibodi
western
blot
antiretin
antibodi
test
done
differ
laboratori
though
major
patient
test
one
commerci
laboratori
usa
supplement
tabl
seven
patient
treatment
time
first
sampl
collect
wherea
patient
system
immunosuppress
treatment
corticosteroid
five
current
untreat
patient
treatment
mean
never
receiv
system
treatment
four
current
treat
patient
receiv
rituximab
infus
studi
period
supplement
tabl
current
evidencebas
scale
assess
diseas
sever
air
measur
outcom
sever
diseas
involv
gradual
chang
erg
gvf
could
use
surrog
diseas
progress
henc
marker
diseas
sever
erg
vari
consider
visit
intersess
variabl
subject
report
even
among
normal
eye
possibl
intersess
variabl
eye
advanc
retin
diseas
fishman
et
al
bach
et
al
take
account
intersess
variabl
purpos
studi
defin
air
diseas
sever
mild
loss
function
moder
sever
loss
photoreceptor
function
erg
defin
lower
limit
normalci
iscev
supplement
tabl
show
raw
erg
data
eye
enrol
particip
first
visit
tabl
also
show
chang
erg
patient
one
sampl
four
particip
stabl
poor
erg
show
modest
declin
despit
addit
anoth
immunomodulatori
agent
total
frozen
serum
sampl
air
patient
receiv
john
hopkin
hospit
nei
nih
air
patient
age
rang
year
gender
distribut
femal
male
addit
blood
obtain
normal
individu
john
hopkin
hospit
serum
sampl
serv
control
studi
eighteen
normal
individu
age
rang
year
gender
distribut
femal
male
use
assay
similarli
eighteen
normal
individu
age
rang
year
gender
distribut
femal
male
use
assay
serum
collect
centrifug
min
sampl
store
freezer
analyz
cytokin
evalu
use
two
technolog
multiplex
immunoassay
enzymelink
immunosorb
assay
eia
air
sampl
analyz
multiplex
system
mask
fashion
analysi
determin
patient
one
serum
sampl
therefor
serum
sampl
obtain
first
clinic
visit
use
data
analysi
use
immunoassay
biorad
laboratori
hercul
ca
sampl
analyz
gmcsf
assay
use
beadbas
flow
cytometr
platform
design
captur
sandwich
immunoassay
format
similar
eia
custom
kit
label
bead
purchas
biorad
laboratori
antibodyco
magnet
bead
specif
gmcsf
median
fluoresc
intens
mfi
determin
instrument
luminex
corpor
austin
tx
use
bioplex
softwar
version
biorad
laboratori
hercul
ca
standard
curv
establish
individu
cytokin
analyz
correspond
concentr
valu
pgml
determin
accord
manufactur
instruct
sampl
run
duplic
mask
fashion
mean
valu
use
final
concentr
cytokin
note
lowest
concentr
detect
system
pgml
multiplex
analysi
reveal
mean
concentr
normal
individu
pgml
rang
pgml
order
examin
predict
valu
marker
air
case
statu
examin
sampl
versu
percentil
pgml
distribut
among
normal
individu
posit
valu
identifi
concentr
greater
percentil
pgml
serum
level
confirm
use
eia
quantikin
r
system
inc
minneapoli
mn
sensit
assay
quantit
low
level
serum
serum
sampl
test
duplic
mask
fashion
accord
manufactur
instruct
plate
read
immedi
applic
stop
solut
optic
densiti
sampl
determin
use
tunabl
micropl
reader
molecular
devic
sunnyval
ca
result
calcul
standard
curv
report
accordingli
picogram
per
millilit
pgml
mean
minimum
detect
dose
mmd
pgml
standard
curv
rang
pgml
pgml
refer
rang
serum
establish
cytokin
laboratori
john
hopkin
univers
use
serum
sampl
normal
individu
analyz
eia
r
system
inc
assay
mean
serum
valu
pgml
rang
pgml
order
examin
predict
valu
marker
air
case
statu
examin
sampl
versu
percentil
pgml
distribut
among
normal
individu
posit
valu
identifi
concentr
greater
percentil
pgml
data
analyz
use
wilcoxon
rank
sum
test
mannwhitney
u
test
compar
mean
concentr
respect
among
follow
untreat
air
case
normal
individu
treat
air
case
normal
individu
air
case
treat
untreat
normal
individu
statist
analys
complet
use
stata
version
statacorp
llc
colleg
station
tx
p
valu
consid
signific
twentyfour
serum
sampl
air
patient
initi
analyz
multiplex
immunoassay
system
presenc
cytokin
chemokin
seen
tabl
sampl
test
lower
limit
quantit
lloq
gmcsf
detect
sampl
detect
sampl
contrast
posit
sampl
patient
sera
posit
sampl
patient
sera
test
sera
individu
air
patient
evalu
possibl
correl
treatment
versu
treatment
diseas
sever
comparison
level
detect
sera
air
patient
normal
individu
shown
tabl
mean
concentr
normal
individu
pgml
rang
pgml
sampl
normal
individu
level
percentil
consid
neg
sixti
one
percent
air
patient
sera
posit
mean
concentr
pgml
tabl
note
seven
air
patient
studi
treatment
time
sera
collect
seen
fig
patient
elev
level
mean
pgml
statist
signific
differ
observ
air
patient
sera
compar
normal
individu
sera
p
moreov
signific
differ
observ
normal
individu
sera
compar
untreat
air
patient
sera
p
compar
treat
air
patient
sera
p
also
clear
distinct
level
compar
sera
untreat
patient
n
treat
patient
n
mean
concentr
pgml
untreat
patient
sera
pgml
treat
patient
sera
fig
use
eia
addit
test
air
patient
sera
perform
seen
tabl
detect
sera
normal
individu
level
percentil
therefor
consid
neg
howev
detect
posit
level
sera
individu
air
thu
identifi
air
patient
sampl
mean
valu
pgml
compar
normal
individu
mean
valu
pgml
comparison
level
treat
untreat
patient
seen
fig
four
untreat
patient
elev
level
mean
pgml
signific
differ
observ
untreat
patient
sera
compar
sera
normal
individu
p
also
clear
distinct
level
compar
sera
untreat
patient
mean
pgml
treat
patient
mean
pgml
interest
note
untreat
patient
elev
level
either
air
patient
stratifi
two
level
diseas
sever
mild
diseas
moderatesever
four
patient
mild
diseas
one
elev
level
anoth
patient
elev
level
last
two
patient
mild
diseas
elev
level
either
cytokin
one
patient
elev
seen
earli
time
point
diseas
cours
treatment
remain
patientssera
mild
diseas
mean
level
pgml
mean
level
pgml
fourteen
patient
sever
diseas
elev
level
elev
level
total
patient
sever
diseas
elev
level
either
patient
sera
mean
level
pgml
mean
level
pgml
data
indic
increas
diseas
sever
trend
toward
elev
five
patient
multipl
serial
collect
serum
sampl
test
comparison
serial
collect
sampl
shown
tabl
first
two
patient
sever
diseas
high
level
third
patient
also
sever
diseas
associ
high
level
sampl
normal
level
contrast
last
patient
mild
diseas
show
normal
level
sampl
normal
level
sampl
data
present
studi
demonstr
increas
inflammatori
molecul
sera
air
patient
moreov
increas
air
diseas
sever
found
associ
increas
proport
concentr
posit
sampl
cytokin
contrast
none
cytokin
analyz
gmcsf
significantli
increas
air
patient
cohort
although
presenc
alway
detect
serum
sampl
patient
sever
diseas
frequent
elev
cytokin
sera
furthermor
level
higher
patient
system
immunomodulatori
treatment
consid
strengthen
possibl
inflamm
may
play
role
pathogenesi
air
howev
whether
lower
cytokin
concentr
among
treat
patient
correspond
clinic
improv
yet
determin
find
elev
underscor
promin
role
cytokin
inflammatori
autoimmun
process
howev
select
cytokin
herein
small
possibl
numer
cytokin
may
elev
depress
cytokin
milieu
may
contribut
elev
addit
research
need
may
reveal
cytokin
particip
degen
process
stimul
inflammatori
process
chemokin
orchestr
immun
cell
migrat
specif
tissu
islam
et
al
increas
evid
clearli
implic
involv
mediat
develop
autoimmun
diseas
exampl
persist
product
associ
caus
onset
develop
autoimmun
hirano
hunter
jone
disord
act
b
cell
stimulatori
factor
activ
b
cell
antibodi
produc
plasma
cell
also
mediat
cell
develop
autoimmun
combin
induc
differenti
cell
cell
therebi
make
avail
within
autoimmun
environ
altern
report
inhibit
abil
induc
regulatori
cell
imbal
implic
onset
progress
autoimmun
diseas
tanaka
kishimoto
presenc
ifn
human
autoimmun
diseas
first
describ
sle
patient
detect
correl
diseas
activ
hook
et
al
presenc
ifn
mani
autoimmun
diseas
recogn
integr
compon
patholog
process
niewold
cytokin
trigger
express
major
function
attract
cell
contain
surfac
site
inflamm
islam
et
al
chemokin
play
critic
role
migrat
cell
blood
vessel
brain
retina
lee
et
al
morrel
et
al
recent
identifi
patient
autoimmun
diseas
anim
model
autoimmun
human
implic
pathogenesi
ra
multipl
sclerosi
loo
et
al
simpson
et
al
furthermor
signatur
enhanc
murin
model
retin
degen
diseas
experiment
coronaviru
retinopathi
ecor
ecor
diseas
trigger
coronaviru
genet
suscept
anim
balbc
mice
associ
antiretin
autoimmun
reactiv
detrick
hook
viru
also
replic
retina
genet
resist
mice
anim
develop
retin
degener
mice
develop
antiretin
antibodi
hook
et
al
detrick
hook
addit
elev
level
detect
sera
enhanc
gene
express
note
retina
earli
diseas
notabl
cytokin
profil
observ
one
day
prior
infiltr
cell
retina
studi
implic
express
develop
retin
autoimmun
anoth
exampl
involv
autoimmun
demonstr
lang
associ
show
product
liver
requir
develop
murin
autoimmun
liver
diseas
lang
et
al
system
liverspecif
cytotox
cell
abl
migrat
infiltr
destroy
liver
cell
express
togeth
data
underscor
import
role
develop
autoimmun
patholog
sinc
air
character
retin
patholog
potenti
sourc
may
within
retina
retin
pigment
epitheli
rpe
cell
retin
vascular
endotheli
cell
rich
sourc
lee
et
al
nagineni
et
al
rpe
cell
possess
tlr
high
concentr
tlr
drive
cytokin
product
kumar
et
al
human
elev
serum
patient
ocular
inflammatori
diseas
associ
sarcoidosi
also
shown
correl
diseas
activ
takeuchi
et
al
interestingli
elev
serum
along
proinflammatori
cytokin
also
report
patient
retin
dystrophi
patient
cytokin
level
decreas
respons
immunomodulatori
treatment
find
suggest
may
signific
contribut
inflamm
known
genet
retin
dystrophi
activ
resid
retin
cell
may
respons
proinflammatori
cytokin
product
verhagen
et
al
clearli
presenc
air
patient
specif
diseas
sinc
molecul
identifi
system
inflammatori
autoimmun
process
moreov
relat
chemokin
identifi
retin
disord
ambati
et
al
notabl
exampl
seen
age
relat
macular
degener
amd
independ
prognost
marker
associ
diseas
progress
seddon
et
al
addit
studi
identifi
highli
express
retina
amd
patient
mo
et
al
whether
cytokin
contribut
retin
patholog
still
unknown
nevertheless
data
present
provid
support
hypothesi
air
pathogenesi
may
associ
inflammatori
process
cytokinemedi
pathway
pivot
develop
autoimmun
diseas
elev
uniqu
air
data
present
indic
inflammatori
cytokin
signatur
elev
may
contribut
retin
patholog
observ
air
patient
continu
studi
pathway
use
discoveri
futur
strategi
air
diagnosi
manag
